If you have tried antidepressant after antidepressant and still feel like you are barely getting by, you are not alone and you have not run out of options. Treatment-resistant depression affects a significant portion of people who seek help for the condition, and for years the options for these patients were frustratingly limited. That has changed with the expanded use of ketamine treatment for depression, which works through a completely different mechanism than conventional antidepressants and has shown strong results for people who have found nothing else effective.
The fundamental problem with standard antidepressants is that they target serotonin, norepinephrine, or dopamine, and they take weeks to build up to a therapeutic level in the brain. For people in acute distress or those who have been cycling through medications for years with little relief, that timeline is not just inconvenient; it is genuinely harmful. Ketamine bypasses those slow-acting pathways entirely. It works on the glutamate system, blocking NMDA receptors and rapidly stimulating the growth of new synaptic connections in the prefrontal cortex. Research published by Mayo Clinic Press on ketamine for treatment-resistant depression explains that this fast-acting mechanism makes it the only current antidepressant option capable of producing meaningful relief within hours rather than weeks.
What Treatment Actually Involves
Most ketamine therapy for depression is delivered as a series of IV infusions over several weeks, typically starting with two sessions per week and gradually tapering as the patient’s symptoms stabilize. Sessions are conducted in a clinical setting with a medical professional present throughout. Patients remain conscious during the infusion but may experience a temporary dissociative sensation that resolves shortly after the session ends. The infusions are typically 40 to 60 minutes each, and many patients begin to notice improvement after just the first few sessions. Esketamine, the nasal spray form of the drug, is an FDA-approved alternative that is also administered in a medical office under supervision.
How Effective Is It
Clinical data on ketamine for treatment-resistant depression is compelling. Response rates in trials have consistently reached 60 to 70 percent among patients who had not responded to conventional treatments—a number that far exceeds what most other options offer in this population. The effects are also meaningfully fast, with many patients reporting a significant reduction in depressive symptoms within 24 hours of their first infusion. Beyond symptom relief, ketamine has shown particular promise in reducing acute suicidal ideation, making it one of the few tools psychiatrists have that can work fast enough to make a real difference in crisis situations.
The NIDA overview of ketamine’s clinical applications notes that while ketamine is not yet FDA-approved for all psychiatric uses, its derivative esketamine has full approval for treatment-resistant depression and that dozens of clinics across the country are offering ketamine itself off-label based on a growing body of evidence supporting its use.
Combining Ketamine with Ongoing Psychiatric Care
Ketamine therapy works best as part of a comprehensive psychiatric treatment plan rather than as a standalone intervention. Many providers integrate it alongside therapy and careful medication management so that the window of neurological openness ketamine creates is used productively. Patients who engage in therapy during or shortly after their ketamine sessions often consolidate their gains more effectively and maintain improvement for longer. For people who have spent years trying to feel better without success, ketamine is not a miracle, but it is a real and meaningful option.